Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG7 | O95352 | 4/20 | 0.40 |
| ▸ | NAE1 | Q13564 | 5/20 | 0.39 |
| ▸ | UBA3 | Q8TBC4 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008037 | 0.86 | ATG7 (0.40) | ATG7NAE1UBA3CA1CA2 | |
| SCHEMBL20007970 | 0.74 | DNPH1 (0.38) | NAE1UBA3 | |
| SCHEMBL23080289 | 0.74 | NAE1 (0.41) | ATG7NAE1UBA3CA1CA2 | |
| SCHEMBL20008382 | 0.72 | ADORA2A (0.32) | ATG7ALDH1A1CYP1A2CYP3A4TSHR | |
| SCHEMBL20008059 | 0.71 | RET (0.33) | ATG7NAE1UBA3 | |
| SCHEMBL18872517 | 0.70 | ATG7 (0.38) | ATG7NAE1CA2ALDH1A1TSHR | |
| SCHEMBL23080272 | 0.70 | CDK1 (0.53) | MAPK1TSHR | |
| SCHEMBL20008212 | 0.69 | ADORA3 (0.34) | NAE1UBA3 | |
| SCHEMBL192481 | 0.69 | NAE1 (0.60) | ATG7NAE1UBA3CA2 | |
| SCHEMBL1801644 | 0.69 | ATG7 (0.66) | ATG7NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | ATG7 1114/4885NAE1 41/4885UBA3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.